about
Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastomaPreclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.Targeted approaches to childhood cancer: progress in drug discovery and development.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroNew approaches for pediatric rhabdomyosarcoma drug discovery: targeting combinatorial signaling.
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Preclinical drug development for childhood cancer.
@en
type
label
Preclinical drug development for childhood cancer.
@en
prefLabel
Preclinical drug development for childhood cancer.
@en
P2093
P2860
P1476
Preclinical drug development for childhood cancer.
@en
P2093
Andrew D J Pearson
Lucas Moreno
Suzanne A Eccles
P2860
P356
10.1517/17460441.2011.537652
P407
P577
2010-11-24T00:00:00Z